<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570011</url>
  </required_header>
  <id_info>
    <org_study_id>822</org_study_id>
    <secondary_id>B9R-EW-GDED</secondary_id>
    <nct_id>NCT00570011</nct_id>
  </id_info>
  <brief_title>Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients</brief_title>
  <official_title>Efficacy of Two Different Dose Regimens of Somatropin in Growth Hormone Deficient Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Naples</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An international study in which patients with GHD were randomized to receive somatropin at a&#xD;
      dose of either 3 microg/kg/day or 6 microg/kg/day for the first three months. The dose was&#xD;
      then doubled (6 microg/kg/day, LD or 12 microg/kg/day, CD) for the next three-months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 1997</start_date>
  <completion_date type="Actual">December 1998</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA) as a function of changes in insulin levels was investigated.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of Leptin, Insulin, IGFBP1, IGFBP2, IGF2</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
    <description>3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>LLY137998</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatropin</intervention_name>
    <description>6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>LLY137998</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients may be included in the study only if they meet all of the following criteria:&#xD;
&#xD;
          1. Adult males and females with GHD, arising during adult life from pituitary ablation or&#xD;
             failure, onset of GHD have taken place at least 1 year before entering the study, or,&#xD;
&#xD;
          2. Adult males and females with GHD either idiopathic or secondary to pituitary disease&#xD;
             arising in childhood.&#xD;
&#xD;
          3. Demonstrated GHD as documented by a negative response to a standard GH stimulation&#xD;
             test within the last 5 years previous year (see Section 3.4.3, part b). Maximal peak&#xD;
             must be less than 3.0 ng/ml.&#xD;
&#xD;
          4. Receiving replacement for other deficient hormones for at least 3 months prior to the&#xD;
             start of the study, where necessary.&#xD;
&#xD;
          5. Have given informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded from the study for any of the following reasons:&#xD;
&#xD;
          1. Patients with clinically significant pulmonary, cardiac, hepatic, renal or&#xD;
             neuromuscular disease or with chromosomal or genetic malformation syndromes.&#xD;
&#xD;
          2. Patients who have any evidence of an active tumorous process. Intercranial lesions&#xD;
             must be inactive and any antitumour therapy must be complete.&#xD;
&#xD;
          3. Pregnant women and lactating females or women who decide to become pregnant during the&#xD;
             study and who are not taking adequate contraceptives.&#xD;
&#xD;
          4. Patients thought unlikely to comply with the protocol.&#xD;
&#xD;
          5. Patients taking an investigational drug in the previous month.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>December 7, 2007</study_first_submitted>
  <study_first_submitted_qc>December 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2007</study_first_posted>
  <last_update_submitted>December 10, 2007</last_update_submitted>
  <last_update_submitted_qc>December 10, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2007</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

